#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	15870	16S	1529	1529	99.8	16S.l15.c17.ctg.1	2362	820.1	0	.	n	.	0	A69G	SNP	69	69	A	472	472	G	970	G,A	711,253	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	15870	16S	1529	1529	99.8	16S.l15.c17.ctg.1	2362	820.1	0	.	n	.	0	C450T	SNP	450	450	C	853	853	T	1058	T,C,G	1054,3,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	15870	16S	1529	1529	99.8	16S.l15.c17.ctg.1	2362	820.1	0	.	n	.	0	C1450T	SNP	1450	1450	C	1853	1853	T	1063	T,C	1061,2	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	15870	16S	1529	1529	99.8	16S.l15.c17.ctg.1	2362	820.1	1	SNP	n	C1184T	0	.	.	1184	1184	C	1587	1587	C	971	C,A	969,2	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27392	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3988	855.7	0	.	n	.	0	G1337A	SNP	1337	1337	G	1879	1879	A	1150	A,T	1148,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27392	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3988	855.7	0	.	n	.	0	T1971C	SNP	1971	1971	T	2513	2513	C	964	C	964	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27392	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3988	855.7	1	SNP	n	A2045G	0	.	.	2045	2045	A	2587	2587	A	913	A,C,G	909,2,2	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27392	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3988	855.7	1	SNP	n	C2597T	0	.	.	2597	2597	C	3139	3139	C	959	C,T,G	957,1,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_K_01359c	folP.WHO_K_01359c	1	1	539	2528	folP	852	852	99.88	folP.l15.c30.ctg.1	2131	147.7	0	.	p	.	0	E151K	NONSYN	451	453	GAA	953	955	AAA	260;263;266	A,T;A,G,C;A	257,2;260,1,1;265	.	.
folP.WHO_K_01359c	folP.WHO_K_01359c	1	1	539	2528	folP	852	852	99.88	folP.l15.c30.ctg.1	2131	147.7	1	SNP	p	R228S	1	.	.	682	684	AGC	1184	1186	AGC	275;271;273	A;G;C	275;271;273	folP.WHO_K_01359c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5580	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3954	175.9	1	SNP	p	S91F	0	.	.	271	273	TCC	828	830	TCC	225;224;223	T;C;C	224;224;222	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5580	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3954	175.9	1	SNP	p	D95N	0	.	.	283	285	GAC	840	842	GAC	229;229;228	G;A,G,T;C	229;227,1,1;228	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5580	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3954	175.9	1	SNP	p	D95G	0	.	.	283	285	GAC	840	842	GAC	229;229;228	G;A,G,T;C	229;227,1,1;228	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	27	2192	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1817	150.3	1	SNP	p	G45D	0	.	.	133	135	GGC	661	663	GGC	249;247;247	G,C;G;C	248,1;247;247	mtrR.WHO_Y_01506:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	1218	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1526	99.6	0	.	n	.	0	A197.	DEL	197	197	A	840	840	A	238	A	238	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	5116	parC	2304	2304	99.78	parC.l15.c4.ctg.1	3380	188.6	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1784	1786	GCA	289;287;285	G;C;A,G	288;286;283,1	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	5116	parC	2304	2304	99.78	parC.l15.c4.ctg.1	3380	188.6	1	SNP	p	D86N	0	.	.	256	258	GAC	737	739	GAC	217;217;218	G;A,T;C,G	217;216,1;217,1	parC.WHO_F_01444:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	5116	parC	2304	2304	99.78	parC.l15.c4.ctg.1	3380	188.6	1	SNP	p	S87W	0	.	.	259	261	AGT	740	742	AGT	219;217;216	A;G;T,G	219;217;215,1	parC.WHO_F_01444:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	5116	parC	2304	2304	99.78	parC.l15.c4.ctg.1	3380	188.6	1	SNP	p	S87I	0	.	.	259	261	AGT	740	742	AGT	219;217;216	A;G;T,G	219;217;215,1	parC.WHO_F_01444:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	5116	parC	2304	2304	99.78	parC.l15.c4.ctg.1	3380	188.6	1	SNP	p	S87R	0	.	.	259	261	AGT	740	742	AGT	219;217;216	A;G;T,G	219;217;215,1	parC.WHO_F_01444:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	5116	parC	2304	2304	99.78	parC.l15.c4.ctg.1	3380	188.6	1	SNP	p	S88P	0	.	.	262	264	TCC	743	745	TCC	217;214;215	T,A;C,A;C	216,1;213,1;215	parC.WHO_F_01444:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4696	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3274	178.8	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1877	1879	GGC	272;270;270	G,C;G;C,T,G,A	270,1;269;266,1,1,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	539	4422	penA	1749	1749	99.94	penA.l15.c4.ctg.1	3003	183.6	1	SNP	p	A502V	1	A502V	NONSYN	1504	1506	GCG	2149	2151	GTG	263;261;262	G;T,G;G	263;258,3;262	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	539	4422	penA	1749	1749	99.94	penA.l15.c4.ctg.1	3003	183.6	1	SNP	p	A311V	0	.	.	931	933	GCA	1576	1578	GCA	259;258;257	G,A;C,A;A,T	258,1;257,1;255,2	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	539	4422	penA	1749	1749	99.94	penA.l15.c4.ctg.1	3003	183.6	1	SNP	p	I312M	0	.	.	934	936	ATC	1579	1581	ATC	260;263;264	A;T,G;C,G	260;262,1;263,1	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	539	4422	penA	1749	1749	99.94	penA.l15.c4.ctg.1	3003	183.6	1	SNP	p	V316P	0	.	.	946	948	GTG	1591	1593	GTG	256;256;258	G;T,G,C;G	255;253,1,1;258	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	539	4422	penA	1749	1749	99.94	penA.l15.c4.ctg.1	3003	183.6	1	SNP	p	V316T	0	.	.	946	948	GTG	1591	1593	GTG	256;256;258	G;T,G,C;G	255;253,1,1;258	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	539	4422	penA	1749	1749	99.94	penA.l15.c4.ctg.1	3003	183.6	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2095	2097	ACC	254;257;258	A,T;C;C	253,1;257;258	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	539	4422	penA	1749	1749	99.94	penA.l15.c4.ctg.1	3003	183.6	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2272	2274	GGC	237;240;242	G;G;C	237;240;242	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	539	4422	penA	1749	1749	99.94	penA.l15.c4.ctg.1	3003	183.6	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2281	2283	GGC	246;247;249	G,T;G;C,G	245,1;247;248,1	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	539	4422	penA	1749	1749	99.94	penA.l15.c4.ctg.1	3003	183.6	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2299	2301	CTG	248;248;247	C,G;T;G	246,1;247;246	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5988	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3442	216.7	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1763	1765	CCG	244;244;242	C;C;G	244;244;242	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2592	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2338	138.0	0	.	p	.	0	M83fs	FSHIFT	247	247	A	894	894	C	178	C	178	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	356	porB1a	984	163	92.64	porB1a.l15.c17.ctg.4	163	59.8	0	.	p	.	0	S271T	NONSYN	811	813	TCG	62	64	ACT	78;78;78	A;C;T	78;78;78	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	356	porB1a	984	163	92.64	porB1a.l15.c17.ctg.4	163	59.8	0	.	p	.	0	Y273D	NONSYN	817	819	TAT	68	70	GAT	78;78;78	G;A;T	78;78;78	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	356	porB1a	984	163	92.64	porB1a.l15.c17.ctg.4	163	59.8	0	.	p	.	0	D274S	NONSYN	820	822	GAT	71	73	AGT	78;78;78	A;G;T	78;78;78	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	356	porB1a	984	163	92.64	porB1a.l15.c17.ctg.4	163	59.8	0	.	p	.	0	D276N	NONSYN	826	828	GAT	77	79	AAC	78;78;78	A;A;C	77;78;78	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	356	porB1a	984	163	92.64	porB1a.l15.c17.ctg.4	163	59.8	0	.	p	.	0	N277H	NONSYN	829	831	AAC	80	82	CAC	78;78;78	C;A;C	78;78;78	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2868	porB1b	1041	1041	96.28	porB1b.l15.c30.ctg.1	1922	184.9	0	.	p	.	0	T89S	NONSYN	265	267	ACC	760	762	AGC	269;266;267	A;G,T;C,T	269;265,1;266,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2868	porB1b	1041	1041	96.28	porB1b.l15.c30.ctg.1	1922	184.9	0	.	p	.	0	.	MULTIPLE	358	359	AA	852	853	CG	219;215	C,A;G,T	218,1;214,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2868	porB1b	1041	1041	96.28	porB1b.l15.c30.ctg.1	1922	184.9	0	.	p	.	0	.	MULTIPLE	361	362	GA	855	857	CAG	217;219;220	C,G;A;G	216,1;219;220	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2868	porB1b	1041	1041	96.28	porB1b.l15.c30.ctg.1	1922	184.9	0	.	p	.	0	N122K	NONSYN	364	366	AAC	859	861	AAA	217;217;217	A;A;A,C	217;217;216,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2868	porB1b	1041	1041	96.28	porB1b.l15.c30.ctg.1	1922	184.9	0	.	p	.	0	F131Y	NONSYN	391	393	TTT	886	888	TAT	256;257;257	T,A;A;T	255,1;257;257	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2868	porB1b	1041	1041	96.28	porB1b.l15.c30.ctg.1	1922	184.9	0	.	p	.	0	N134E	NONSYN	400	402	AAT	895	897	GAG	254;254;254	G,C;A,C;G	253,1;253,1;254	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2868	porB1b	1041	1041	96.28	porB1b.l15.c30.ctg.1	1922	184.9	0	.	p	.	0	V135F	NONSYN	403	405	GTG	898	900	TTT	252;253;250	T,A;T,C;T	251,1;252,1;250	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2868	porB1b	1041	1041	96.28	porB1b.l15.c30.ctg.1	1922	184.9	0	.	p	.	0	G140K	NONSYN	418	420	GGA	913	915	AAA	268;273;275	A,C;A,G;A	267,1;271,2;275	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2868	porB1b	1041	1041	96.28	porB1b.l15.c30.ctg.1	1922	184.9	0	.	p	.	0	K143E	NONSYN	427	429	AAA	922	924	GAA	271;269;269	G,T;A,C;A,C,T	270,1;268,1;265,3,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2868	porB1b	1041	1041	96.28	porB1b.l15.c30.ctg.1	1922	184.9	0	.	p	.	0	V151A	NONSYN	451	453	GTA	946	948	GCA	264;264;266	G,A;C;A	263,1;264;266	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2868	porB1b	1041	1041	96.28	porB1b.l15.c30.ctg.1	1922	184.9	0	.	p	.	0	Y212H	NONSYN	634	636	TAT	1129	1131	CAT	298;300;301	C,A;A,G,C,T;T	297,1;297,1,1,1;301	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2868	porB1b	1041	1041	96.28	porB1b.l15.c30.ctg.1	1922	184.9	0	.	p	.	0	T213L	NONSYN	637	639	ACA	1132	1134	TTA	301;301;306	TTATATA,TTATA;T;A	285,1;301;306	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2868	porB1b	1041	1041	96.28	porB1b.l15.c30.ctg.1	1922	184.9	0	.	p	.	0	A244V	NONSYN	730	732	GCA	1225	1227	GTA	259;257;256	G;T;A,T,C	259;257;254,1,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2868	porB1b	1041	1041	96.28	porB1b.l15.c30.ctg.1	1922	184.9	0	.	p	.	0	G253Q	NONSYN	757	759	GGA	1252	1254	CAA	199;195;192	C;A,G;A,G	199;194,1;191,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2868	porB1b	1041	1041	96.28	porB1b.l15.c30.ctg.1	1922	184.9	0	.	p	.	0	.	INDELS	760	762	ACA	1256	1260	ATCAA	186;184;181;177;175	A;T,G;C;A,G;A,C	186;183,1;181;176,1;174,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2868	porB1b	1041	1041	96.28	porB1b.l15.c30.ctg.1	1922	184.9	0	.	p	.	0	.	INDELS	763	764	TG	1263	1265	AGT	173;171;170	A;G,T;T	173;170,1;170	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2868	porB1b	1041	1041	96.28	porB1b.l15.c30.ctg.1	1922	184.9	0	.	p	.	0	A257D	NONSYN	769	771	GCT	1270	1272	GAT	169;168;168	G;A,C;T	169;167,1;168	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2868	porB1b	1041	1041	96.28	porB1b.l15.c30.ctg.1	1922	184.9	0	.	p	.	0	V270A	NONSYN	808	810	GTA	1309	1311	GCG	195;195;193	G;C;G	195;195;193	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2868	porB1b	1041	1041	96.28	porB1b.l15.c30.ctg.1	1922	184.9	0	.	p	.	0	D293S	NONSYN	877	879	GAT	1378	1380	AGT	222;223;224	A;G;T	222;223;224	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2868	porB1b	1041	1041	96.28	porB1b.l15.c30.ctg.1	1922	184.9	1	SNP	p	G120K	1	.	.	358	360	AAG	852	854	CGG	219;215;214	C,A;G,T;G	218,1;214,1;214	porB1b.WHO_M_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2868	porB1b	1041	1041	96.28	porB1b.l15.c30.ctg.1	1922	184.9	1	SNP	p	A121D	1	.	.	361	363	GAC	855	858	CGC	217;220;219	C,G;G;C	216,1;220;219	porB1b.WHO_M_02204c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2868	porB1b	1041	1041	96.28	porB1b.l15.c30.ctg.1	1922	184.9	1	SNP	p	D121N	0	.	.	361	363	GAC	855	858	CGC	217;220;219	C,G;G;C	216,1;220;219	porB1b.WHO_M_02204c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	10898	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5273	257.2	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2275	2277	CAT	275;277;280	C;A,C;T	275;275,2;280	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1506	rpsJ	312	312	100.0	rpsJ.l6.c4.ctg.1	1462	128.5	1	SNP	p	V57M	1	.	.	169	171	ATG	705	707	ATG	253;253;253	A;T;G	253;253;253	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
